•
Dec 31, 2024
Aytu BioScience Q2 2025 Earnings Report
Expected Revenue:$0
-100.0% YoY
Expected EPS:$0
+100.0% YoY
Key Takeaways
Aytu BioPharma reported a net income of $0.8 million and an adjusted EBITDA of $1.3 million for the second quarter of fiscal year 2025. The company achieved positive sequential prescription growth across both its ADHD and Pediatric portfolios, a first since late-2022. The company's cash and cash equivalents were $20.4 million as of December 31, 2024.
Net income was $0.8 million.
Adjusted EBITDA was $1.3 million.
Pediatric Portfolio net revenue increased 86% sequentially.
Both ADHD and Pediatric portfolios experienced first quarterly sequential prescription increase since Q2 fiscal 2023.
Aytu BioScience
Aytu BioScience
Forward Guidance
Aytu anticipates revenue and adjusted EBITDA growth from current levels as it strives for positive cash flows.